Pliant Therapeutics (NASDAQ:PLRX) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Pliant Therapeutics (NASDAQ:PLRX) announced its quarterly earnings data on Thursday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.02), FiscalAI reports.

Pliant Therapeutics Stock Performance

Pliant Therapeutics stock opened at $0.74 on Friday. The business has a fifty day moving average of $0.98 and a two-hundred day moving average of $1.14. Pliant Therapeutics has a twelve month low of $0.73 and a twelve month high of $1.80.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PLRX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pliant Therapeutics in a research report on Thursday, October 15th. Wall Street Zen downgraded Pliant Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.00.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver. Pliant’s lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins αvβ1 and αvβ6.